PFE Dividends
Pfizer Inc. (PFE) pays $1.72 in dividends per share, with a current dividend yield of 6.70%. The company has dividend history for 15 consecutive years.
PFE Dividend Summary
6.70%
$1.72
126.47%
103.06%
Consecutive Years
15
Most Recent Ex-Date
May 8, 2026
Next Payment Date
Jun 12, 2026
PFE Dividends per Share (Nominal History)
View full nominal table listThis step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency.
PFE Dividends CAGR Chart
Pfizer Inc. (PFE)
Annual Dividend History
| Year | Dividend/Share | YoY Growth |
|---|---|---|
| 2026(YTD) | $0.86 | — |
| 2025 | $1.72 | +2.38% |
| 2024 | $1.68 | +2.44% |
| 2023 | $1.64 | +2.50% |
| 2022 | $1.60 | +2.56% |
| 2021 | $1.56 | +2.63% |
| 2020 | $1.52 | +5.56% |
| 2019 | $1.44 | +5.88% |
| 2018 | $1.36 | +6.25% |
| 2017 | $1.28 | +12.60% |
| 2016 | $1.14 | +1.50% |
| 2015 | $1.12 | +7.69% |
| 2014 | $1.04 | +8.33% |
| 2013 | $0.96 | +9.09% |
| 2012 | $0.88 | +16.12% |
| 2011 | $0.76 | +5.26% |
| 2010 | $0.72 | -7.06% |
| 2009 | $0.77 | -36.11% |
| 2008 | $1.21 | +10.35% |
| 2007 | $1.10 | +20.70% |
Quarterly Dividend History
| Quarter | Dividend/Share | YoY Growth |
|---|---|---|
| Q2 2026 | $0.43 | +0.00% |
| Q1 2026 | $0.43 | +0.00% |
| Q4 2025 | $0.43 | +2.38% |
| Q3 2025 | $0.43 | +2.38% |
| Q2 2025 | $0.43 | +2.38% |
| Q1 2025 | $0.43 | +2.38% |
| Q4 2024 | $0.42 | +2.44% |
| Q3 2024 | $0.42 | +2.44% |
| Q2 2024 | $0.42 | +2.44% |
| Q1 2024 | $0.42 | +2.44% |
| Q4 2023 | $0.41 | +2.50% |
| Q3 2023 | $0.41 | +2.50% |
| Q2 2023 | $0.41 | +2.50% |
| Q1 2023 | $0.41 | +2.50% |
| Q4 2022 | $0.40 | +2.56% |
| Q3 2022 | $0.40 | +2.56% |
| Q2 2022 | $0.40 | +2.56% |
| Q1 2022 | $0.40 | +2.56% |
| Q4 2021 | $0.39 | +2.63% |
| Q3 2021 | $0.39 | +2.63% |
| Q2 2021 | $0.39 | +2.63% |
| Q1 2021 | $0.39 | +2.63% |
| Q4 2020 | $0.38 | +5.56% |
| Q3 2020 | $0.38 | +5.56% |
Dividend Yield Metrics
- Current Yield
- 6.70%
- Average Yield (TTM)
- 6.70%
- Average Yield (3Y)
- 6.55%
- Forward Yield on Cost (3Y)
- 7.39%
- Forward Yield on Cost (5Y)
- 7.89%
- Forward Yield on Cost (10Y)
- 9.28%
Payout Ratio Analysis
- Payout Ratio (Current)
- 126.47%
- FCF Payout Ratio
- 103.06%
- Payout Ratio (3Y Avg)
- 227.18%
- Payout Ratio (5Y Avg)
- 149.92%
- FCF Payout (3Y Avg)
- 132.51%
- FCF Payout (5Y Avg)
- 92.25%
Dividend Coverage
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla